Abstract
Objective
Elevation of homocysteine and thioredoxin (Trx) levels was found in some patients
with coronary artery diseases (CAD). However, their correlations with CAD were not
clear. Dysfunction of thioredoxin/thioredoxin reductase (TrxR) may cause oxidative
stress that is common to CAD. We seek to determine the association among homocysteine,
Trx/TrxR and CAD.
Methods
Serum samples were collected from 150 CAD patients under statin treatment and 122
non-CAD controls. Risk factors for atherosclerosis including homocysteine, lipids
and glucose levels were analyzed. Trx/TrxR activities and protein levels were determined
using super-insulin assay and Western blot, respectively. One-way ANOVA, Tukey's post
hoc test and Spearman's rank correlation coefficient were used for statistical analysis.
CAD severity was evaluated by angiographic Gensini score.
Results
Compared with non-CAD group, CAD group had significantly increased TrxR activity (P < 0.05) and homocysteine levels (P < 0.01), but not Trx activity. After further dividing CAD group using homocysteine below
15 μM as reference, Trx activity decreased significantly in CAD group with high homocysteine,
and was inversely associated with homocysteine levels (r = −0.199, P < 0.05) that was, however, weakly positively associated with TrxR activity. Neither
lipids nor glucose significantly affected Trx/TrxR activity. Association of CAD severity
with low Trx plus high homocysteine was strong (r = −0.458, P < 0.001), but with high homocysteine alone was rather weak (r = 0.125, P = 0.225).
Conclusion
In CAD patients, high homocysteine levels may cause low Trx activity, which is closely
correlated to the extent and severity of CAD.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to AtherosclerosisAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Plasma homocysteine levels and mortality in patients with coronary artery disease.N Engl J Med. 1997; 337: 230-236
- Homocysteine and redox signaling.Antioxid Redox Signal. 2005; 7: 547-559
- Mechanisms of homocysteine-induced oxidative stress.Am J Physiol Heart Circ Physiol. 2005; 289: H2649-H2656
- Regulatory role of thioredoxin in homocysteine-induced monocyte chemoattractant protein-1 secretion in monocytes/macrophages.FEBS Lett. 2008; 582: 3893-3898
- Thioredoxin-linked peroxidase from human red blood cell: evidence for the existence of thioredoxin and thioredoxin reductase in human red blood cell.Biochem Biophys Res Commun. 1995; 217: 900-907
- Thioredoxin as a reducing agent for mammalian methionine sulfoxide reductases B lacking resolving cysteine.Biochem Biophys Res Commun. 2008; 371: 490-494
- The relationship of the redox potentials of thioredoxin and thioredoxin reductase from Drosophila melanogaster to the enzymatic mechanism: reduced thioredoxin is the reductant of glutathione in Drosophila.Biochemistry. 2007; 46: 7875-7885
- Thioredoxin.Annu Biochem Rev. 1985; 54: 237-271
- Differential role of glutaredoxin and thioredoxin in metabolic oxidative stress-induced activation of apoptosis signal-regulating kinase 1.Biochem J. 2003; 373: 845-853
- Thiol redox control via thioredoxin and glutaredoxin systems.Biochem Soc Trans. 2005; 33: 1375-1377
- Mammalian thioredoxin reductases as hydroperoxide reductases.Methods Enzymol. 2002; 347: 236-243
- Human thioredoxin reductase directly reduces lipid hydroperoxides by NADPH and selenocystine strongly stimulates the reaction via catalytically generated selenols.J Biol Chem. 1995; 270: 11761-11764
- Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase.J Biol Chem. 1997; 272: 22607-22610
- Protein denitrosylation: enzymatic mechanisms and cellular functions.Nat Rev Mol Cell Biol. 2009; 10: 721-732
- Physiological functions of thioredoxin and thioredoxin reductase.Eur J Biochem. 2000; 267: 6102-6109
- Oxidized LDL induces a coordinated up-regulation of the glutathione and thioredoxin systems in human macrophages.Atherosclerosis. 2006; 185: 282-289
- Secretion of 10-kDa and 12-kDa thioredoxin species from blood monocytes and transformed leukocytes.Antioxid Redox Signal. 2000; 2: 717-726
- Increased plasma levels of thioredoxin in patients with glucose intolerance.Intern Med. 2005; 44: 1127-1132
- Increased plasma thioredoxin in patients with acute myocardial infarction.Clin Cardiol. 2003; 26: 583-587
- Thioredoxin in coronary culprit lesions: possible relationship to oxidative stress and intraplaque hemorrhage.Atherosclerosis. 2008; 201: 360-367
- Plasma homocyst(e)ine and arterial occlusive diseases: a mini-review.Clin Chem. 1995; 41: 173-176
- A more meaningful scoring system for determining the severity of coronary heart disease.Am J Cardiol. 1983; 51: 606
- a singlet oxygen quencher and hydroxyl radical scavenger: redox independent functions.Biochem Biophys Res Commun. 2000; 277: 443-447
- Thioredoxin negatively regulates p38 MAP kinase activation and IL-6 production by tumor necrosis factor-alpha.Biochem Biophys Res Commun. 1999; 258: 443-447
- Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer.Structure. 1996; 4: 735-751
- Homocysteine and glutathione peroxidase-1.Antioxid Redox Signal. 2007; 9: 1923-1940
- Induction of thioltransferase and thioredoxin/thioredoxin reductase systems in cultured porcine lenses under oxidative stress.Invest Ophthalmol Vis Sci. 2005; 46: 3783-3789
- Up-regulation of defense enzymes is responsible for low reactive oxygen species in malignant prostate cancer cells.Exp Mol Med. 2005; 37: 497-506
- Penultimate selenocysteine residue replaced by cysteine in thioredoxin reductase from selenium-deficient rat liver.FASEB J. 2009; 23: 2394-2402
- Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure.Am Heart J. 2007; 153: 471-477
Article info
Publication history
Published online: July 01, 2010
Accepted:
June 1,
2010
Received in revised form:
May 13,
2010
Received:
January 12,
2010
Identification
Copyright
© 2010 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.
